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Endorepellin, the C-terminal fragment of the heparan sulfate
proteoglycan perlecan, influences various signaling pathways in
endothelial cells by binding to VEGFR2. In this study, we discov-
ered that soluble endorepellin activates the canonical stress
signaling pathway consisting of PERK, eIF2, ATF4, and
GADD45. Specifically, endorepellin evoked transient activa-
tion of VEGFR2, which, in turn, phosphorylated PERK at Thr980.
Subsequently, PERK phosphorylated eIF2 at Ser51, upregulat-
ing its downstream effector proteins ATF4 and GADD45.
RNAi-mediated knockdown of PERK or eIF2 abrogated the
endorepellin-mediated up-regulation of GADD45, the ulti-
mate effector protein of this stress signaling cascade. To func-
tionally validate these findings, we utilized an ex vivo model of
angiogenesis. Exposure of the aortic rings embedded in 3D
fibrillar collagen to recombinant endorepellin for 2– 4 h acti-
vated PERK and induced GADD45 vis à vis vehicle-treated
counterparts. Similar effects were obtained with the established
cellular stress inducer tunicamycin. Notably, chronic exposure
of aortic rings to endorepellin for 7–9 days markedly suppressed
vessel sprouting, an angiostatic effect that was rescued by block-
ing PERK kinase activity. Our findings unravel a mechanism by
which an extracellular matrix protein evokes stress signaling in
endothelial cells, which leads to angiostasis.
Perlecan, one of the largest heparan sulfate proteoglycans of
basement membranes and cell surfaces, plays a major role in
vasculogenesis and angiogenesis (1). For instance, morpholino-
based knockdown of perlecan in zebrafish causes profound dis-
ruption of all vessels formed via angiogenesis from the dorsal
aorta and other major blood vessels (2).
In mice, the effect of global perlecan knockdown is even
more pronounced, as perlecan-null mice (Hspg2/) are em-
bryonic lethal because of intrapericardial hemorrhage and mal-
formation of coronary arteries and cardiac outflow tracts (3).
Perlecan expression is finely regulated during cardiovascular
development (4, 5) and is one of the few extracellular matrix
constituents expressed in vascular and avascular matrices.
Perlecan is a modular proteoglycan composed of five do-
mains that are involved in growth factor regulation, cancer,
inflammation, lipid metabolism, basement membrane assem-
bly, cell adhesion, and mechanosensing, among many other
reported functions (6 –16). The parent protein perlecan is pro-
angiogenic because of the presence of three heparan sulfate
chains covalently attached at its N terminus, which act as a
reservoir of growth factors. In contrast, the C-terminal module
of perlecan, called endorepellin (17, 18), is anti-angiogenic and
inhibits cancer progression by interfering with the blood supply
of the growing tumors (19 –21).
Endorepellin interacts with VEGFR2 via its two proximal
laminin-like globular (LG1/2)3 domains and to the 21 integ-
rin via its terminal LG3 module, evoking dual receptor antago-
nism (22, 23). Indeed, soluble endorepellin inhibits angio-
genesis by interfering with several VEGFR2-evoked signaling
pathways, primarily by evoking transcriptional repression of
hypoxia-inducible factor 1 (HIF-1) and vascular endothelial
growth factor A (VEGFA) and concurrently inhibiting nuclear
factor of activated T cells (NFAT1) (24). We recently discov-
ered a link between endorepellin-induced inhibition of angio-
genesis and autophagy in endothelial cells (20). In our quest to
find novel autophagic targets for endorepellin through NanoS-
tring analysis (25), we discovered that the mRNA of growth
arrest and DNA damage–inducible (GADD45) protein was
dynamically regulated by the endorepellin/VEGFR2 axis. This
protein has been reported to have a dual role: one in activating
autophagy and the other in inhibiting angiogenesis (25). As an
angiogenic suppressor, GADD45 interacts with mTOR and
prevents Stat3 phosphorylation from driving VEGFA expres-
sion, inhibiting angiogenesis (26). As an autophagy inducer,
GADD45 inhibits mTOR and induces the levels of LC3-II, an
autophagic marker (27).
GADD45 belongs to the canonical PKR-like endoplasmic
reticulum kinase (PERK)/eIF2/activating transcription factor
4 (ATF4)/GADD45 axis, which is usually activated by external
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hypoxia, or oxidative stress (28, 29). Notably, ATF4 promotes
skeletal muscle atrophy via a unique interaction with the tran-
scriptional regulator C/EBP (30). All of these external stimuli
are known to trigger the unfolded protein response, which ulti-
mately leads to stress activation in cells (31, 32). The stress
pathway was originally considered to help cells cope with stress
stimuli by promoting survival. However, under prolonged
stress, the survival mechanism can switch to cellular elimina-
tion via autophagic activation, which can eventually lead to cell
death. For instance, in glioblastoma cells, eIF2 phosphoryla-
tion can up-regulate ATF4 levels, which induce autophagy by
mTORC1 inhibition, causing cell death (33). Alternatively,
ATF4 can lead to accumulation of transcription factor CCAAT-
enhancer-binding protein homologous protein and apoptotic
induction by GADD34 activation in endothelial cells (34). Pro-
tein misfolding was originally understood to be essential for
activating intracellular stress; however, more recent discoveries
have shown that ligand–receptor interactions (i.e. estrogen
receptor 1 with 3,3-bis(4-hydroxyphenyl)-7-methyl-1,3-di-
hydro-2H-indol-2-one) also activate stress and cellular necrosis
(35). Together, these reports suggest that the PERK/eIF2/
ATF4/GADD45 stress axis can be activated in cells without
accumulation of misfolded proteins.
Given that endorepellin and GADD45 concurrently evoke
autophagy and angiostasis, we hypothesized that the biological
repertoire of endorepellin could include activation of a stress
signaling pathway in vascular endothelial cells. We discovered
that endorepellin evoked profound and sustained stress signal-
ing in in vitro and ex vivo models of angiogenesis primarily by
interacting with VEGFR2. Our studies highlight the role of
endorepellin in inducing the stress pathway. This, in turn,
would significantly curtail the generation of new vessels in
the tumor matrix with clear implications for impeding can-
cer progression.
Results
Endorepellin induces GADD45 by evoking a stress signaling
axis
To dissect the mechanism involved in endorepellin-evoked
anti-angiogenic activity, we investigated GADD45, a gene that
is highly modulated in a NanoString analysis of endothelial cells
exposed to recombinant endorepellin (25). The rationale is
based on the fact that GADD45 increases in response to var-
ious stressors (28, 36) and suppresses tumor angiogenesis by
blocking the mTOR pathway (26) while concurrently inducing
LC3 (37). Moreover, the GADD45–mTOR interaction pre-
vents Stat3 phosphorylation from driving VEGFA expression,
inhibiting angiogenesis (26). We performed time course exper-
iments using the same concentrations of endorepellin (200 nM)
under nutrient-rich conditions as in the NanoString studies
(25). We discovered that endorepellin evoked a rapid and sus-
tained increase in GADD45 (Fig. 1, A and B). As GADD45 is
known to be induced by ATF4 (38), we tested ATF4 levels in
parallel experiments. We found a significant induction of ATF4
that peaked at 3 h and declined thereafter (Fig. 1, A and B).
ATF4 is known to be regulated by phosphorylation of eIF2,
the  subunit of eukaryotic initiation factor 2 (39). Phosphoryl-
ation of eIF2 at Ser51 results in global protein synthesis sup-
pression and plays a key role in response to various stresses,
such as viral infection, buildup of misfolded proteins, and
starvation. Paradoxically, phosphorylation of eIF2 at Ser51
induces transcription and translation of ATF4 (40). There are
only four eIF2 mammalian kinases (PERK, heme-regulated
inhibitor, PKR, and GCN2) (29, 39, 41), all of which phosphor-
ylate eIF2 at Ser51, leading to similar downstream effects. In
initial screenings, we found that human umbilical vein endo-
thelial cells (HUVECs) predominantly express PERK, PKR, and
GCN2 (Fig. S1A). Thus, we tested PERK and found time-depen-
dent phosphorylation of PERK at Thr980 within its catalytic site
(42), evoked by endorepellin (Fig. 1, C and D). Moreover, we
found sustained activation of eIF2 at Ser51 (Fig. 1, C and D).
We note that activation of PERK occurred rapidly, peaking at
1 h and preceding that of eIF2 (Fig. 1, C and D). We also
saw temporal phosphorylation of PERK by LG1/2 domains of
endorepellin, but not LG3, mirroring the effect of endorepellin
(Fig. S1, C–F). As an internal positive control, we utilized tuni-
camycin, an antibiotic that inhibits N-linked glycosylation and
induces the unfolded protein response (43) (Fig. S1B).
To address the mechanism of stress signaling induction by
exogenous endorepellin, we blocked the VEGFR2 kinase with
the small-molecule inhibitor SU5416 (44, 45) and found com-
plete suppression of endorepellin-evoked PERK (Fig. 1E). Thus, it
appears that VEGFR2 is directly involved in endorepellin biologi-
cal activity, in agreement with our previous studies (20, 24, 45).
Next we performed imaging and cell fractionation to ascer-
tain whether GADD45 and its activator ATF4 would translo-
cate into the nuclei of stressed endothelial cells, as shown
before in other cells (46, 47). We discovered that endorepellin
evoked marked nuclear translocation of GADD45 at 4 h, sim-
ilar to that induced by tunicamycin (Fig. 1, F and G). Cell frac-
tionation studies followed by endorepellin treatment for 4 h
showed that the trimeric form of GADD45 (68 –72 kDa dou-
blet, Fig. 1H) that was mainly observed in the nucleus under
basal conditions, as seen in other studies (46), was markedly
increased by endorepellin (Fig. 1H). In contrast, the monomeric
form of GADD45 (22 kDa) did not change appreciably (Fig.
1H). In support of these findings, ATF4 levels and nuclear
translocation were concurrently increased in HUVECs at 4 h
(Fig. 1, I and J). These findings were further validated in two
other endothelial cell models, telomerase human aortic endo-
thelial cells (TeloHAECs) and porcine aortic endothelial cells
expressing VEGFR2 (PAER2s). Notably, we found even faster
induction of PERK phosphorylation, with maximal activation at
30 min in TeloHAECs (Fig. S2, A–C) compared with HUVECs,
where p-PERK peaked at 1 h (Fig. 1C). In PAER2s, the kinetics of
PERK phosphorylation at Thr980 were similar to that of HUVECs
(Fig. S2, E–G). These biochemical data were corroborated by im-
munofluorescence studies, which showed up-regulation of
p-PERK and GADD45 in TeloHAECs and PAER2s together with
nuclear translocation of GADD45 (Fig. S2, C and G).
Collectively, our results provide the first evidence that
endorepellin activates the PERK/eIF2/ATF4/GADD45 stress
signaling pathway. This could be a dynamic nexus for endorepellin
bioactivity connecting stress signaling and angiostasis.
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PERK and eIF2 are required for endorepellin-dependent
stress axis induction
To confirm the biological relevance of PERK and eIF2 in
endorepellin-mediated activation of stress signaling, we tran-
siently depleted these two proteins via RNAi in HUVECs. We
observed that PERK depletion (80% knockdown) led to sig-
nificant abrogation of eIF2 phosphorylation at Ser51 induced
by endorepellin or tunicamycin (Fig. 2, A and B). Notably, even
basal eIF2 phosphorylation at Ser51 was suppressed by PERK
depletion (Fig. 2, A and B), further indicating a primary role of
PERK as the key kinase regulating eIF2 phosphorylation in
vascular endothelial cells.
Next we found that, when eIF2 was depleted (90% knock-
down), there was marked suppression of GADD45 under
Figure 1. Endorepellin evokes phosphorylation of PERK/eIF2 and up-regulation of ATF-4/GADD45 downstream of VEGFR2. A, representative
immunoblots of time course experiments of HUVECs treated with endorepellin (200 nM, ranging from 0 – 6 h) and probed for ATF4 and GADD45. Data were
obtained from endorepellin-treated HUVECs from three independent experiments (n  3) and normalized to GAPDH. B, quantification of ATF4 and GADD45
from A. C, representative immunoblots of time course experiments of HUVECs treated with endorepellin (200 nM, 0 – 6 h) and probed for p-PERKThr980, total
PERK, p-eIF2Ser51, and total eIF2. Data were acquired from three independent experiments (n  3) and normalized to their respective total protein levels. D,
quantification of p-PERKThr980 and p-eIF2Ser51 from C. One-way ANOVA was performed on all data. E, immunoblots of time course experiments of HUVECs
pretreated for 30 min with SU5416 (a VEGR2 kinase inhibitor, 30 M), followed by addition of endorepellin ranging from 0 –24 h. The last lane shows the positive
control, i.e. endorepellin alone for 2 h. -Tubulin served as the loading control. F, immunofluorescence images of HUVECs showing cytoplasmic or nuclear
distribution of GADD45 (red) seen with respect to DAPI (blue) after treatment with vehicle (PBS), endorepellin (200 nM), or tunicamycin (10 g/ml) for 4 h.
Nuclear localization of GADD45 is seen as a magenta hue under endorepellin or tunicamycin treatment conditions because of the merging of red and blue
tones in the nucleus. G, quantification of cells with nuclear localization of GADD45 from F. An average of 100 cells per treatment (vehicle, endorepellin, or
tunicamycin) were analyzed from five independent experiments. H, representative immunoblots of cell fractionation experiments of HUVECs treated for 3 h
with or without endorepellin (200 nM). The membranes were probed for lamin A/C to label nuclear fractions (Nu), GAPDH to label cytoplasmic fractions (Cy), and
GADD45. Only the nuclear fraction was enriched in the trimeric form of GADD45, and these levels were increased by exposure to endorepellin. I, immuno-
fluorescence images of HUVECs treated with vehicle, endorepellin, or tunicamycin for 4 h and probed for filamentous actin (red) and ATF4 (green). The nuclei
are outlined by dotted lines. J, quantification of cells with nuclear localization of ATF4 from I. An average of 500 cells per treatment (vehicle, endorepellin, or
tunicamycin) were analyzed from three independent experiments (n  3). All statistical analyses were calculated via one-way ANOVA (***, p  0.001).
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basal conditions as well as endorepellin or tunicamycin treat-
ments (Fig. 2, C and D). Collectively, our results underscore the
requirement of PERK as the major activator of the endorepel-
lin-evoked stress axis in endothelial cells and provide novel
mechanistic insights into sequential activation of the PERK/
eIF2/GADD45 axis by endorepellin.
Endorepellin activates the stress pathway in ex vivo
angiogenic assays
To directly test whether the anti-angiogenic activity of
endorepellin was associated with induction of stress signaling,
we performed ex vivo aortic ring assays in 3D type I fibrillar
collagen (48). Fully sprouted explanted aortic rings of C57BL/6J
mice were subjected to acute treatment with endorepellin
or tunicamycin using the same in vitro concentrations. For
p-PERK induction, we used 2-h treatment, the time point at
which we observed maximal PERK phosphorylation (cf. Fig.
1C). For confocal imaging, we utilized isolectin IB4, which spe-
cifically binds to galactosyl residues on endothelial cells (49,
50), and antibodies against p-PERK at Thr980, considered a
marker for its activation status (51–53). We found a marked
increase in p-PERK evoked by endorepellin or tunicamycin
(Fig. 3A). These effects could be clearly seen using the line-
scanning tool, as described under “Experimental procedures”
(Fig. 3B). Quantification of four independent experiments
using three randomly selected aortic rings per mouse showed
significant induction of p-PERK, measured as fluorescence
intensity of the sprouted area normalized on the area occupied
by the vascular sprouts (p  0.001, Fig. 3C and Fig. S3B). We
confirmed the endothelial nature of the sprouts by staining with
a second endothelial cell marker, CD31 (red), and counterstain-
ing with P-PERK (green) (Fig. S3D). We obtained similar results
as those shown for IB4 and p-PERK staining (Fig. 3A).
To validate our confocal imaging studies, we next performed
biochemical analysis of rings treated with endorepellin or tuni-
camycin for 2 h. We first pooled two aortic rings per sample and
removed the rings after solubilization with radioimmune pre-
cipitation assay buffer. Thus, the protein extracts were com-
posed exclusively of sprouted endothelial cells growing in 3D
collagen. In agreement with the confocal imaging studies, we
found marked induction of p-PERK at Thr980 evoked by either
treatment (Fig. 3, D and E).
Next we probed for GADD45, the ultimate effector protein
of the stress axis. Interestingly, we observed that GADD45
was not appreciably altered at 2 h (not shown) but markedly
Figure 2. Endorepellin-dependent PERK and eIF2 activation is essential for downstream GADD45 up-regulation. A, representative immunoblots of
HUVECs pretreated with 100 pM scrambled siRNA (siScr) or siRNA targeting PERK (siPERK), followed by treatment with endorepellin (200 nM) or tunicamycin (10
g/ml). Lysates show RNAi-mediated knockdown of PERK (siPERK) and subsequent suppression of eIF2 phosphorylation. Treatment conditions are indicated
in the bottom panel. B, quantification of PERK and p-eIF2 from A, normalized on GAPDH for PERK or total protein level for P-eIF2. Data are from three
independent biological experiments (n  3). C, representative immunoblots of HUVECs pretreated with 100 pM scrambled siRNA (siScr) or with siRNA targeting
eIF2 (sieIF2), followed by treatment with endorepellin (200 nM) or tunicamycin (10 g/ml). Lysates show RNAi-mediated knockdown of eIF2 (sieIF2) and
subsequent suppression of GADD45 levels. D, quantification of eIF2 and GADD45 from C, normalized to GAPDH. Data are from three independent
experiments (n  3). Statistical significance was calculated via two-tailed unpaired Student’s t test (**, p  0.01). All statistical analyses were calculated via
one-way ANOVA (***, p  0.001).
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increased at 4 h of treatment with endorepellin or tunicamycin
(Fig. 4A). Quantification of four independent experiments
using three randomly selected aortic rings per mouse showed
significant induction of GADD45 (p  0.001, Fig. 4B), as
determined by the fluorescence intensity of the sprouted area,
measured as described under “Experimental procedures” (Fig.
S3B). In agreement with the confocal imaging, we found by
immunoblotting that endorepellin or tunicamycin markedly
induced GADD45 (Fig. 4, C and D). Collectively, these ex vivo
functional assays corroborate the in vitro results and show pro-
gressive activation of the stress signaling pathway, where PERK
is first phosphorylated at Thr980, followed by an increase in
GADD45 levels.
The endorepellin-activated stress axis inhibits angiogenesis
To further investigate the specificity of endorepellin-evoked
PERK activation, we utilized a small-molecule inhibitor,
GSK2656157, a cell-permeable, ATP-competitive inhibitor of
PERK (PERKi) (54). This small molecule is exquisitely specific
for PERK with more than 100-fold selectivity for PERK over
other eIF2 kinases (55) and an IC50 of 1 nM in various cells, as
shown by inhibition of PERK autophosphorylation, eIF2 phos-
phorylation, and ATF4 suppression (55). Oral administration
of this PERKi results in tumor suppression and angiostasis (55),
consistent with reduced tumor growth in Perk/ mice (56).
We found that the PERKi efficiently blocked the activity of
endorepellin in a dose-dependent manner (Fig. 5A) with an
Figure 3. Endorepellin activates PERK in sprouts of ex vivo aortic rings. A, representative confocal images of aortic rings following treatment with
endorepellin (200 nM) or tunicamycin (10 g/ml) for 2 h. Endothelial cells in sprouts were visualized with isolectin IB4 (red), a marker for endothelial cells, and
counterstained with an antibody against P-PERKThr980 (green). Insets show magnified sprouts stained for p-PERKThr980. B, line intensity profiles of PERK (green)
expression in aortic ring sprouts corresponding to the yellow line traced along the enlarged image of sprouts in the inset in A. C, quantification of the
fluorescence intensity of PERK in the sprouted area from A; fluorescence intensity data are from a total of 12 vehicle (Veh)-, nine endorepellin (Endo)-, and
10 tunicamycin (Tunic)-treated aortic rings from four independent experiments (n  4). D, representative immunoblots of three pooled, sprouted blood
vessels probed for p-PERKThr980 and total PERK. E, quantification of p-PERKThr980 levels over total PERK from D. Three aortic rings were pooled per
condition (vehicle, endorepellin, or tunicamycin) and repeated four times; therefore, four independent experiments were performed (n  4). The data
are derived only from newly formed sprouts, as the aortic rings were removed before solubilization. All statistical analyses were calculated via one-way
ANOVA (***, p  0.001).
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IC50 of 10 nM (Fig. 5B). Notably, we observed a parallel reduc-
tion in phosphorylation of downstream eIF2 at Ser51 (Fig. 5A)
with an IC50 of 1 nM (Fig. 5B). We also confirmed that
GSK2656157 was 1000-fold more potent in inhibiting PERK
phosphorylation in HUVECs with an IC50 of 1 nM (Fig. 5A)
compared with another PERK inhibitor, AMG44, which was
discovered recently and has an IC50 of 1000 nM in HUVECs
(Fig. S3C).
Next we performed functional aortic ring assays in 3D type I
collagen using the PERKi with or without endorepellin. In these
experiments, we added the PERKi or endorepellin after 3 days,
when we detected the first sprouts. We added fresh PERKi (10
nM) or endorepellin (200 nM) every other day and continued the
treatment for 9 days in total. At the end of the chronic treat-
ment, we observed a drastic abrogation of ring sprouting in
endorepellin-treated rings (Fig. 5C) vis à vis vehicle (p  0.001,
Fig. 5D). However, the PERKi completely blocked the angio-
static activity of endorepellin (Fig. 5, C and D). We acquired
phase-contrast images of the rings and calculated the radial
distance of the sprouts by subtracting the background and
highlighting sprouts using the threshold function in ImageJ.
We then drew circles around the rings, encompassing the edges
of the sprouts, and measured the radii (Fig. S3A). Next we
labeled the rings with IB4 and DAPI, and, using confocal laser
scanning microscopy, we obtained comparable qualitative (Fig.
5E) and quantitative (Fig. 5F) findings. Collectively, our results
suggest that endorepellin-dependent inhibition of angiogenesis
requires activation of the PERK–stress axis.
Discussion
Classical pathways evoked by protracted activation of the
unfolded protein response and ER stress are known to interfere
with angiogenesis (57). Specifically, the PERK/eIF2/ATF4/
GADD45 pathway, a major ER stress signaling axis, can gen-
erate angiomodulatory and angiostatic cues (57). Although this
axis is usually activated under stressful stimuli, such as osmotic/
oxidative stress, irradiation, or nutrient deprivation, it may also
be activated in the absence of external stresses (58). In this
study, we present endorepellin-mediated activation of this
stress axis through ligand–receptor interaction in the absence
Figure 4. Endorepellin up-regulates the effector protein GADD45 in aortic rings. A, representative confocal images of aortic rings following treatment
with endorepellin (200 nM) or tunicamycin (10 g/ml) for 4 h. Sprouts were labeled with IB4 (red) and GADD45 (green). Insets, magnified sprouts stained for IB4
(red), GADD45 (green), and DAPI (blue). B, quantification of the fluorescence intensity of GADD45 for the sprouted area from A. Fluorescence intensity data
are from a total of 10 vehicle (Veh)-, eight endorepellin (Endo)-, and eight tunicamycin (Tunic)-treated aortic rings from four independent experiments (n  4).
C, representative immunoblots of three pooled, sprouted blood vessels probed for GADD45. GAPDH was used as a loading control. D, quantification of
GADD45 levels normalized to GAPDH from C. Data are from four independent biological experiments (n  4), with each condition comprised of three pooled
sprouts. All statistical analyses were calculated via one-way ANOVA (***, p  0.001).
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of external stress. We provide a working model summarizing
our current findings regarding the mechanism of action for
endorepellin-evoked endothelial cell stress (Fig. 6). According
to this model, endorepellin engages the ectodomain of VEGFR2
via LG1/2 globular domains, acting as a partial agonist
and evoking phosphorylation of the receptor tyrosine kinase
Tyr1175, a key residue from which the canonical phospholipase
C- cascade originates (59). Phosphorylation of VEGFR2 at
Tyr1175 is necessary for stress activation because downstream
signaling is completely abrogated by inhibiting VEGFR2 kinase
activity with SU5416 (44, 45). The signal emanating from
VEGFR2 causes activation of the stress-sensing kinase PERK at
Thr980. PERK activation subsequently leads to eIF2 phosphor-
ylation at Ser51, enhanced translation of ATF4, and up-regula-
tion of GADD45 (Fig. 6). ATF4 and GADD45 translocate
into the nucleus, where, presumably, a number of anti-angio-
genic and pro-autophagic genes are induced. Ultimately,
endorepellin-mediated activation of the stress axis causes inhi-
bition of angiogenesis.
The path to this study was paved by identification of
GADD45 as one the targets of endorepellin in endothelial
cells, as discovered by NanoString analysis (25). As GADD45
is a part of the stress axis and is modulated by endorepellin in
endothelial cells, we hypothesized that GADD45 may affect
angiogenesis. We found that GADD45 up-regulation inhibits
angiogenesis. These data are in congruence with a previous
study that showed that GADD45 inhibits tumor angiogenesis
in mice injected with transformed mouse embryonic fibroblasts
(26). Interestingly, we saw up-regulation of GADD45 and
upstream stress axis proteins upon endorepellin treatment but
a down-regulation of GADD45 mRNA evoked by endorepel-
lin. A plausible cause of this observation may be mRNA degra-
Figure 5. PERK inhibition blocks endorepellin-dependent stress signaling and angiostasis in aortic rings. A, representative immunoblots of dose-de-
pendent experiments of HUVECs pretreated with the PERKi for 30 min, followed by endorepellin (200 nM) exposure for 1 h and 30 min. Blots were probed for
p-PERK and p-eIF2. -Tubulin served as the loading control. B, quantification of p-PERK and p-eIF2 from A, with normalization to their respective
total protein. Data are from three independent biological experiments (n  3), plotted as mean  S.E. One-way ANOVA was performed on the data. C,
representative phase-contrast images of aortic rings treated with endorepellin or endorepellin and the PERKi for 7 days in total after sprouting. D, quantifica-
tion of the radial distance of endorepellin- or endorepellin and PERKi–treated sprouts from C. Phase-contrast data are from 12 vehicle-, 10 endorepellin-, and
10 endorepellin and PERKi–treated rings from four independent experiments (n  4). E, representative confocal images of aortic rings treated with endorepel-
lin or endorepellin and PERKi–treated rings. Rings were labeled with IB4 (red) and DAPI (blue). F, quantification of fluorescence intensity of the sprouted area
from E. Confocal data are from eight vehicle-, eight endorepellin-, and nine endorepellin and PERKi–treated rings from four independent biological experi-
ments (n  4). All statistical analyses were calculated via one-way ANOVA (***, p  0.001).
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dation by microRNA, which may act on surplus GADD45
being formed. Notably, a GADD45-repressing microRNA,
miR-362-5p, promotes malignancy of chronic myelocytic
leukemia cells (60). Another possibility is that there is simulta-
neous stabilization of GADD45, which usually requires an
accessory protein, such as S7 ribosomal protein, to prevent its
ubiquitination and degradation (61). In future studies, it would
be interesting to unravel how the endorepellin–VEGFR2 inter-
action leads to stabilization of GADD45 in endothelial cells;
this could help us to better understand vascular stress.
A critical observation in this study was sustained nuclear
translocation of GADD45 evoked by soluble endorepellin.
Previous studies have shown that nuclear GADD45 interacts
with proliferating cell nuclear antigen, protein 21 (p21Waf1),
and cell division control 2 (Cdc2), playing a role in DNA repair
as a checkpoint protein to prevent a severely damaged cell from
proliferating (28). More recently, a novel role of GADD45 has
been reported in causing DNA demethylation (62). Specifically,
GADD45 recruits the demethylase TET1 at the promoter of
the powerful transcription factor TCF21 (62). This bioactivity
provides an explanation for the mechanism of epigenetic regu-
lation by GADD45. We hypothesize that GADD45 may play
a direct role in demethylating anti-angiogenic and pro-au-
tophagic gene promoters. Especially important are genes that
are known to be controlled by differential methylation, includ-
ing paternally expressed gene 3 (Peg3) which is differentially
methylated in paternal and maternal alleles (63). Notably, we
discovered that Peg3 is a master regulator of autophagy (64) and
is markedly induced at the mRNA and protein levels in endo-
thelial cells exposed to endorepellin (45). Moreover, we found
that overexpression of Peg3 concurrently evokes transcrip-
tional up-regulation of pro-autophagic Beclin 1 and anti-angio-
genic thrombospondin 1 (65).
To unravel the mechanism of action of endorepellin-induced
activation of the canonical PERK/eIF2/ATF4/GADD45
stress axis, we performed inhibitory studies of PERK, the most
upstream molecule of the stress axis. We used two independent
approaches to inhibit PERK action: we knocked down total
PERK using RNAi, and we blocked PERK phosphorylation with
a specific-kinase small-molecule inhibitor. Notably, genetic
and pharmacological inhibitors of PERK markedly suppressed
the downstream stress signaling pathway. These results were
further validated by knockdown of eIF2, which also efficiently
blocked the downstream effectors of this stress axis. Use of
PERK inhibitors required careful selection of the most efficient
inhibitory molecule from the cohort of available drugs. Of the
two most recently reported PERK inhibitors, GSK2656157
and AMG44, we selected GSK2656157 (55, 66). Although
GSK2656157 is the most extensively studied PERK inhibitor
and tumor repressor (55), with an IC50 of 10 nM (55) and
kinase inhibition, AMG44 has a higher specificity for PERK.
Unfortunately, the IC50 for AMG44 is 84 nM, which is eight
times that of GSK2656157, making GSK2656157 the more
effective inhibitor (66). To confirm these findings, using both
inhibitors in dose–response studies in HUVECs revealed a
greater difference in their efficiencies, with GSK2656157 hav-
ing a 1000-fold higher capability of inhibiting PERK phosphor-
ylation (IC50, 1 nM) compared with AMG44 (IC50, 1000
nM). Because the advantages of GSK2656157 outweighed that
of AMG44, we used GSK2656157 to block PERK phosphoryla-
tion and study its impact on angiogenesis. Overall, our results
support a high degree of specificity for GSK2656157 because we
had the same effects by suppressing PERK with a pool of three
to five PERK-specific siRNAs.
The mode of activation of PERK determines its ultimate
mechanism of action. For instance, VEGFA-based PERK
activation leads to induction of angiogenesis (58), whereas
endorepellin-based PERK induction causes angiostasis. This
opposing effect could in part be attributed to allosteric inhibi-
tion of VEGFA by endorepellin (20). This response could also
be due to differential binding of VEGFA and endorepellin to
VEGFR2. Indeed, VEGFA binds VEGFR2 at position 2–3 of
the immunoglobulin-like sub-domains’ on the extracellular
domain, whereas endorepellin binds at position 3– 4 of the
immunonoglobulin-like sub-domains (20, 22). This raises the
strong possibility that they may evoke distinct VEGFR2 phos-
phorylation signatures, leading to activation of diverse down-
stream signaling pathways. Stress axes are mainly comprised of
three pathways: PERK, IRE1, and ATF6. Notably, VEGF simul-
taneously activates two of these stress pathways, PERK (eIF2)
and ATF6 (58), in contrast to endorepellin, which activates
the former. However, we cannot exclude the possibility that
endorepellin may also be involved in the ATF6 pathway.
Figure 6. Working model elucidating the mechanism of endorepellin-
based stress activation via VEGFR2 and subsequent inhibition of angio-
genesis. See text for details.
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A novel and unique aspect of our study is the combination
of biochemical and confocal imaging assays performed on
sprouted capillary-like vessels emanating from aortic rings
grown in a 3D collagen network. This ex vivo assay is a useful
model to study angiogenesis insofar as the sprouts emerging
from the aorta are purely endothelial in nature, with only a
minute layer of pericytes supporting the sprouting vessels (67).
This allowed us to efficiently dissect the angiogenic vessels and
the effects of soluble endorepellin, tunicamycin, and PERK
inhibitor. We successfully demonstrated endorepellin-based
activation of the stress axis in the rings and concurrent abroga-
tion of sprouting by performing imaging and biochemical anal-
ysis, providing robust evidence of protracted stress inhibiting
angiogenesis in the mouse system.
One of the limitations of the aortic ring assay is the lack of
blood flow through the newly formed vessels, which is essential
for hemodynamic and mechanochemical functions (67). How-
ever, as this study focuses only on endorepellin’s effect on for-
mation of neovessels and activation of stress proteins, the
absence of blood flow does not have a negative impact on our
results. Another challenge concerning the aortic ring assay
is reliable quantification of neovessel formation. Different
techniques have been described previously (68 –70). These
methods mainly include counting the sprouts or evaluating the
branching patterns. However, counting sprouts can be chal-
lenging, especially when the sprouts are numerous and densely
packed. A hurdle of quantifying branching pattern is inconsis-
tency in network formation, which may lead to erroneous cal-
culations. To circumvent these issues, we modified the quanti-
fication process by using fluorescently labeled rings (marked
with IB4 or CD31) to trace the area of vascularization or sprout-
ing and compared the angiogenic footprint between different
conditions. As our approach excludes the ring area and exclu-
sively focuses on the newly formed vessel sprouts and branches,
it is very sensitive in obtaining detailed information. The mar-
gin of error is also primarily reduced because of digital pro-
cessing and quantification of fluorescence and not manual eval-
uation of phase-contrast images.
The discovery of activation of the stress pathway by
endorepellin is important because the effector molecule
GADD45 is the convergence point for various pathways (28).
For instance, GADD45 is known to inhibit mTOR and may
have a role in evoking autophagy in endothelial cells, leading to
angiostasis (26). GADD45 could be the connector protein
between the two processes, induction of autophagy and sup-
pression of angiogenesis, which we have proposed in our previ-
ous studies (20, 45). It would be interesting to evaluate the
role of GADD45 in enabling cross-talk between these
two pathways. This study reinforces previous findings that
endorepellin induces broad activation of many anti-angiogenic
pathways. We showed previously that endorepellin inhibits the
PI3K/PDK1/Akt and PKC/c-Jun N-terminal kinase/AP1 axes,
which subsequently inhibit HIF1- and AP1-based VEGFA
promoter activation, inhibiting angiogenesis (24). Additionally,
we recently discovered that endorepellin induces autophagic
degradation of hyaluronan synthase 2 (HAS2), the major pro-
ducer of pro-angiogenic and pro-inflammatory hyaluronan.
This, in turn, evokes dynamic interaction of HAS2 and ATG9A
and downstream angiogenic inhibition in vascular endothelia
(71). Thus, endorepellin could evoke multiple pathways in
endothelial cells emanating from its interaction with VEGFR2,
which would synergistically block angiogenesis.
Endorepellin-based shotgun activation of these pathways
ensures failsafe inhibition of angiogenesis, making it a viable
candidate for combinatorial treatment. Overactivation of stress
in the vasculature using endorepellin could be used to enhance
susceptibility of endothelial cells to antiangiogenic drugs. Nota-
bly, hyperactivation of the stress axis in myeloma cells evoked
by proteasome inhibitors enhances susceptibility to chemo-
therapy (72). Even though endorepellin does not target cancer
cells directly, the concept of stress hyperactivation making cells
susceptible to annihilation by drugs could be applied in the
antiangiogenic paradigm.
Collectively, our findings posit endorepellin as an activator of
cellular stress that simultaneously inhibits angiogenesis and
evokes autophagy. Given this information, endorepellin may
prove to be a protein-based therapeutic agent for overcom-
ing drug resistance against angiogenic inhibitors and, thus,
improve cancer therapy. Furthermore, we believe that subse-
quent investigation will add more extracellular matrix proteins
to the list of stress activators and bring to the surface many
more key players associated with the stress axis. Thus, we
attribute an additional meaningful function to endorepellin’s
already extensive repertoire and further underscore the impor-
tance of the extracellular matrix in improving cancer therapy.
Experimental procedures
Cells and materials
HUVECs were procured from Lifeline Cell Technology
(Frederick, MD) and maintained in basal medium supple-
mented with the VascuLife EnGS LifeFactors Kit (Lifeline Cell
Technology). HUVECs were cultured in cell culture dishes
treated with 0.2% gelatin (Thermo Fisher Scientific, Waltham,
MA) and used within the first four passages. In all experiments,
excluding the knockdown experiments, HUVECs were cul-
tured to full confluence for 2 days to make them quiescent.
TeloHAECs were procured from the ATCC (Manassas, VA)
and grown in Endothelial Cell Growth Medium 2 (EGM-2
SingleQuot Kit Supplements and Growth Factors, Lonza,
Walkersville, MD). Porcine aortic endothelial cells expressing
VEGFR2 (PAER2) have been described before (73, 74). They
were cultured in DMEM (Gibco) with 10% FBS, 1% PenStrep
containing G418 (250 g/ml) (Thermo Fisher Scientific) as the
antibiotic selection agent. HeLa and Epstein–Barr nuclear anti-
gen cells were grown in DMEM with 10% FBS and 1% PenStrep.
Primary rabbit monoclonal antibodies against PERK (D11A8),
eIF2 (D7D3), ATF4 (D4B8), GADD45 (D17E8), and GAPDH
(14C10) were obtained from Cell Signaling Technology (Dan-
vers, MA), and rabbit monoclonal for p- eIF2 (ab32157) were
from Abcam (Cambridge, MA). Primary rabbit mAb against
p-PERK at Thr980 (3179) was obtained from Cell Signaling
Technology. Primary mouse mAb against -tubulin (TU-02),
heme-regulated inhibitor (sc-365239), PKR (sc-6282), and
GCN2 (sc-374609) were purchased from Santa Cruz Biotech-
nology. Mouse mAb against CD31 was obtained from BD
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Pharmingen (553370). For immunoblots, all primary antibodies
were used at 1:1000 dilution, except GAPDH, which was used at
1:10,000. Secondary antibodies were used at 1:4000 dilution.
For immunofluorescence studies, primary antibodies were
used at a concentration of 1:200 and secondary antibodies at a
dilution of 1:400. HRP-conjugated goat anti-rabbit secondary
antibody (AP307P) was obtained from Millipore (Billerica,
MA), and HRP-conjugated goat anti-mouse secondary anti-
body (W4021) was obtained from Promega (Madison, WI).
Alexa Fluor 488 goat anti-mouse (A11001), Alexa Fluor 568
goat anti-mouse (A11004), Alexa Fluor 488 donkey anti-rabbit
(A21206), and Alexa Fluor 488 goat anti-rabbit (A11008) sec-
ondary antibodies were obtained from Thermo Fisher. Isolectin
GS-IB4 Alexa Fluor 594 (I21413) was obtained from Thermo
Fisher and used at a dilution of 1:400. Recombinant human
endorepellin, LG1/2, and LG3 were produced and purified
in the laboratory as described previously (17, 45). Tunicamy-
cin was obtained from Sigma (T7765), PERK inhibitor II
(GSK2656157, 504651) from Millipore, AMG44 from Tocris
(5517), and SU5416 from Calbiochem (676487).
Nuclear fractionation and immunoblotting
HUVECs (106 cells) treated with vehicle or endorepellin for
4 h were harvested and spun down at 500  g for 5 min. Pelleted
cells were washed in PBS, and fractionation was performed
using NE-PER nuclear and cytoplasmic extraction reagent
(78833, Thermo Scientific). The nuclear pellets were washed
twice with PBS to remove any cytoplasmic contaminants before
extraction. To perform Western blotting, following treatment,
endothelial cells were lysed using radioimmune precipitation
assay buffer (50 mM Tris-HCl, 50 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 0.5% sodium deoxycholate, 1 mM
sodium orthovanadate, 0.5% SDS, 1 g/ml leupeptin, 1 g/ml
aprotinin, 1 mM PMSF, 100 M L-1-tosylamido-2-phenylethyl
chloromethyl ketone, and 1 EDTA-free protease inhibitor tab-
let) for 20 min while rocking on ice. Proteins were separated on
an SDS-PAGE gel, transferred to a nitrocellulose membrane
(Bio-Rad), incubated with the appropriate antibodies, and visu-
alized using SuperSignal West Pico chemiluminescence sub-
strate (Thermo Scientific) and an Image Quant LAS-4000 (GE
Healthcare).
Immunofluorescence and confocal laser microscopy
HUVECs (5  104 cells) were grown on gelatin-coated
four-chambered slides (Thermo Fisher Scientific) and given the
stipulated treatments, and then the cells were briefly washed
with PBS and fixed with 4% (w/v) paraformaldehyde for 20 min
on ice (75). Cells were blocked in 1% BSA for 1 h, washed three
times in PBS, incubated with primary antibodies for 1 h, washed
three times in PBS (76), and then incubated with secondary
antibodies for 1 h, as described before (77, 78). Stained cells
were mounted using a hard-set mounting medium containing
DAPI (Vector Laboratories, Burlingame, CA) and sealed with a
coverslip. Immunofluorescence images were captured using
63 objective on a Leica DM5500B microscope installed with
Leica Application Suite v1.8 software (Leica Microsystems,
Frankfurt, Germany). For higher-resolution images, confocal
microscopy was used, and images were captured using a 63,
1.3 oil immersion objective of a Zeiss LSM-780 confocal
laser-scanning microscope equipped with the Zen Imaging
software. Images were acquired as single optical sections of 1
m and collected with the pinhole set to 1 Airy unit for all
channels. Post-acquisition, images were analyzed/processed
using ImageJ and Photoshop CS6 (Adobe Systems).
siRNA-mediated knockdown
Individual transient knockdown of PERK and eIF2 was
achieved in HUVECs using siRNA specific for PERK (sc-36213)
or eIF2 (sc-35272). Scrambled siRNA (sc-37007) was used as
the negative control. HUVECs (2  105 cells/well) were
seeded in 6-well plates to achieve 80% confluence after
attachment and transfected with 100 pM siScr, siPERK, or
sieIF2 and 10 l of Lipofectamine RNAiMax (Life Technolo-
gies) diluted in 150 l of serum-free Opti-MEM medium
(Gibco) overnight. The following day, medium containing
siRNA was aspirated, and cells were incubated in 250 l/well
Lifeline Cell Technology medium containing 4% FBS and 1%
PenStrep for 1 day. On day 3, 4% medium was replaced with 2%
FBS-containing medium. On day 4, we started respective treat-
ments with vehicle (PBS), endorepellin (200 nM), or tunicamy-
cin (10 g/ml). siRNA-mediated knockdown of PERK or eIF2
was verified by immunoblotting. Cell lysates were further ana-
lyzed by immunoblotting for proteins downstream of PERK
and eIF2.
Aortic ring assay
For all animal-based experiments, instructions were fol-
lowed according to the Guide for Care and Use of Laboratory
Animals and the Institutional Animal Care and Use Committee
of Thomas Jefferson University. Thoracic aortae from 6- to
7-week-old WT C57/BL6 mice (The Jackson Laboratory) were
surgically isolated, cleaned off the fibro-adipose tissue, and sec-
tioned serially into 0.5- to 1-mm rings. Rings were sandwiched
between two 3D collagen type I gel layers (1 mg/ml) in 48-well
plates and incubated in EGM-2 medium (Lonza) at 37 °C as
described elsewhere (48, 79). Following initial sprouting,
i.e. 3 days after embedding, the rings were given acute or
chronic treatment. For immediate measurement of stress
induction, rings were treated acutely (2– 4 h) with vehicle
(PBS), endorepellin (200 nM), or tunicamycin (10 g/ml). They
were subsequently processed for immunofluorescence or
Western blotting. For observing long-term effects of the re-
agents on sprouting, the rings were grown over 10 days with
alternative-day treatment of vehicle (PBS), endorepellin (200
nm), tunicamycin (10 g/ml), or PERKi. The rings were then
processed for immunofluorescence or Western blotting.
Processing the aortic ring data
Sprouting of the rings was measured as radial distance using
low-magnification (5) phase-contrast images (79). We sub-
tracted the background and highlighted sprouts using the
threshold function. Then we manually encircled the edges of
the sprouts and measured the radii (Fig. S3A).
During the immunofluorescence analyses, the rings were
labeled with IB4, CD31, p-PERK, and GADD45. Z-stack
images of the rings were captured with a Zeiss LSM780 NLO
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confocal/multiphoton microscope, and the images were ana-
lyzed using ImageJ software. Two methods of analyses were
used: fluorescence of the traced-out sprouts (79) and intensity
profiles of the sprouts, both using ImageJ. Briefly, fluorescence
intensity was uniformly normalized across all conditions using
the threshold function, and regions of interest outlining the
sprouts were selected using the polygon drawing tool. We then
measured the integrated intensity of the traced areas (Fig. S3B)
and normalized on the frame areas. The normalized fluores-
cence intensity of each protein was plotted as the mean fluores-
cence intensity. IB4 or CD31 expression was also used to quan-
tify the extent of sprouting in the rings. We also performed
line-scanning analyses of protein levels in the sprouts using the
profile plot tool in ImageJ. A line was drawn along the sprout,
and fluorescence intensity was measured along the length.
Quantification and statistical analysis
The immunoblots were analyzed by scanning densitometry
using ImageJ. Statistical significance was calculated by two-
tailed, unpaired Student’s t test. One-way ANOVA was per-
formed on data with multiple groups. All experiments were
conducted at least three times, and the mean differences were
considered significant at p  0.05.
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